SCHEMBL4937823

SCHEMBL4937823

COc1ccc(C2=NN(c3ccc(OCC(N)=O)cc3)C(=O)C(C)(C)C2)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 9/20 0.47
PDE4A P27815 3/20 0.44
PDE4C Q08493 3/20 0.44
PDE4D Q08499 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
PDE5A O76074 1/20 0.42
POLB P06746 2/20 0.41
MAPT P10636 1/20 0.41
PDCD1 Q15116 1/20 0.40
CD274 Q9NZQ7 1/20 0.40
TP53 P04637 2/20 0.40
MAOB P27338 1/20 0.40
BLM P54132 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ACACA Q13085 1/20 0.39
ATM Q13315 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4943419 0.86 TP53 (0.55) POLBMAPTTP53
Hydrochloric Acid SCHEMBL4942882 0.86 TP53 (0.49) PDE4BMEN1KMT2APOLBMAPT
SCHEMBL4944690 0.84 PDE5A (0.53) PDE4BPDE4APDE4CPDE4DMEN1
SCHEMBL4944537 0.84 PDE4B (0.51) PDE4BPDE4APDE4CPDE4DMEN1
SCHEMBL4945670 0.84 PDE4B (0.51) PDE4BPDE4APDE4CPDE4DPDE5A
SCHEMBL4937419 0.82 PDE4B (0.53) PDE4BPDE4APDE4CPDE4DPDE5A
SCHEMBL4940552 0.81 PDE4B (0.51) PDE4BPDE4APDE4CPDE4DPDCD1
SCHEMBL4943052 0.78 PDE4B (0.53) PDE4BPDE4APDE4CPDE4DMEN1
SCHEMBL4942500 0.78 MAPT (0.48) PDE4BPDE4APDE4CPDE4DMEN1
SCHEMBL4937607 0.77 MAPT (0.54) PDE4BPDE4APDE4CPDE4DMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227790-A1 Pyridazinone Derivatives and their Use as Pde4 Inhibitors ALTANA PHARMA AG (DE) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227790-A1 Pyridazinone Derivatives and their Use as Pde4 Inhibitors PDE4A, PDE4B, PDE5A PDE4B 2/4885PDE4A 1/4885PDE4C 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.